Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions

British Journal of Dermatology

Volumn 160, Issue 2, 2009, Pages 273-283

  Schutte D ^a   UmBoock, A ^b   Pluschke, G ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Leprosy Relief Emmaus Switzerland (ALES) Cameroon   (Cameroon)

Author keywords

Antibiotic treatment; Cellular immune response; Immunohistochemistry; Intracellular macrophages; Mycobacterium ulcerans

Indexed keywords

RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; ARTICLE; BURULI ULCER; CASE REPORT; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GRANULOMA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MACROPHAGE; MALE; MYCOBACTERIUM ULCERANS; PHAGOCYTOSIS; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BURULI ULCER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GRANULOMA; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PHAGOCYTOSIS; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 58349091459     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08879.x     Document Type: Article

References (31)

1. George KM, Pascopella L, Welty DM, Small PLC. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000 68 : 877 83.
2. Read JK, Heggie CM, Meyers WM, Connor DH. Cytotoxic activity of Mycobacterium ulcerans. Infect Immun 1974 9 : 1114 22.
3. George KM, Chatterjee D, Gunawardana G et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999 283 : 854 7.
4. Asiedu K, Scherpbier RW, Raviglione M. Buruli Ulcer, Mycobacterium UlceransInfection. Geneva : World Health Organization, 2000.
5. Debacker M, Aguiar J, Steunou C et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 2004 9 : 1297 304.
6. Debacker M, Aguiar J, Steunou C et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 2004 10 : 1391 8.
7. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999 354 : 1013 18.
8. Johnson PD, Stinear T, Small PL et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2005 2 : e108.
9. Ellen DE, Stienstra Y, Teelken MA et al. Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli Ulcer Functional Limitation Score. Trop Med Int Health 2003 8 : 90 6.
10. Amofah G, Asamoah S, Afram-Gyening C. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 1998 28 : 81 3.
11. Kanga JM, Kacou DE, Sangare A et al. Recurrence after surgical treatment of Buruli ulcer in Cote d'Ivoire [In French]. Bull Soc Pathol Exot 2003 96 : 406 9.
12. Teelken MA, Stienstra Y, Ellen DE et al. Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 2003 88 : 51 6.
13. World Health Organization. Provisional Guidance on the Role of Specific Antibiotics in the Management of Mycobacterium UlceransDisease (Buruli Ulcer). Geneva : WHO, 2004.
14. O'Brien DP, Hughes AJ, Cheng AC et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007 186 : 58 61.
15. Chauty A, Ardant MF, Adeye A et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007 51 : 4029 35.
16. Burchard GD, Bierther M. Buruli ulcer - clinical pathological study of 23 patients in Lambarene, Gabon. Trop Med Parasitol 1986 37 : 1 8.
17. Rondini S, Horsfield C, Mensah-Quainoo E et al. Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 2006 208 : 119 28.
18. Guarner J, Bartlett J, Whitney EA et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 2003 9 : 651 6.
19. George KM, Barker LP, Welty DM, Small PL. Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun 1998 66 : 587 93.
20. Adusumilli S, Mve-Obiang A, Sparer T et al. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 2005 7 : 1295 304.
21. Prevot G, Bourreau E, Pascalis H et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004 72 : 958 65.
22. Kiszewski AE, Becerril E, Aguilar LD et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 2006 143 : 445 51.
23. Torrado E, Fraga AG, Castro AG et al. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 2006 75 : 977 87.
24. Peduzzi E, Groeper C, Schutte D et al. Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol 2007 127 : 638 45.
25. Schutte D, Um-Boock A, Mensah-Quainoo E et al. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 2007 1 : e2.
26. Etuaful S, Carbonnelle B, Grosset J et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005 49 : 3182 6.
27. Hayman J. Out of Africa - observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol 1993 46 : 5 9.
28. Torrado E, Adusumilli S, Fraga AG et al. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007 75 : 3979 88.
29. Deshpande V, Kapila K, Singh MK, Verma K. Neuritic Hansen's disease: an unusual presentation and a diagnostic challenge on fine-needle aspirate. Diagn Cytopathol 1998 19 : 198 200.
30. Mve-Obiang A, Lee RE, Portaels F, Small PLC. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 2003 71 : 774 83.
31. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol 2006 208 : 261 9.